Interviews - Page 2

Keeping up with fast-paced clinical, regulatory, and policy innovation in healthcare is difficult. Our video interviews provide insight from key experts in the field of biosimilars, and help keep you informed.
Rhett Wilkerson, associate director of patient financial services, Florida Cancer Specialists, discusses financial toxicity in cancer care.
Robin Shah, chief commercial officer of OneOncology, addresses how practices can communicate the value of biosimilars to patients.
 
Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses how route of administration impacts patient adherence to inflammatory bowel disease (IBD) therapy.
Tracy L. Bahl, president and chief executive officer of OneOncology, discusses why his organization felt it was key to adopt biosimilars.
Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd, discusses the role that biosimilars have to play in reducing patients’ out-of-pocket costs in cancer care. 
Terrill Jordan, chief executive officer of Regional Cancer Care Associates (RCCA), discusses how RCCA is handling biosimilar availability.
Rhett Wilkerson, associate director of patient financial services, Florida Cancer Specialists, discusses the role biosimilars have to play in reducing patient costs. 
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses the need for practice-wide education concerning biosimilars in cancer care.
 
Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc, addresses the role that biosimilars will have in alternative payment models in oncology.
 
Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses the role of therapeutic drug monitoring in treating patients with inflammatory bowel disease (IBD).
 

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.